# Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

> **NCT07095686** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **n-Lorem Foundation** · enrollment: 9 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** nL-CHCHD-001

## Key facts

- **NCT ID:** NCT07095686
- **Lead sponsor:** n-Lorem Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-02
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07095686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07095686, "Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07095686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*